|

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

RECRUITINGSponsored by Ain Shams University
Actively Recruiting
SponsorAin Shams University
Started2025-05-05
Est. completion2026-05
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07057765

Summary

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years and ≤ 65 years
* Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
* Any stage of disease (nodal or extra-nodal), with or without B symptoms
* Scheduled to receive standard systemic treatment (R-CHOP)
* ECOG performance status 0-2
* Baseline normal:
* Complete blood count (CBC)
* Hepatitis viral markers
* Liver and renal function tests
* Urine analysis
* Echocardiogram
* Additional investigations to exclude current infection if clinically indicated

Exclusion Criteria:

* History of other concurrent or previous malignancies
* Relapsed or refractory DLBCL
* Uncontrolled comorbid conditions that may interfere with study participation, including:
* Diabetes mellitus
* Autoimmune diseases
* Active infections
* Chronic inflammatory diseases
* Cardiac dysfunction
* Liver cell failure
* Pregnant females

Conditions3

CancerDLBCL - Diffuse Large B Cell LymphomaMarkers of Inflammation

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.